Shares of Health Care sector company BioMarin Pharmaceutical moved 0.7% today, and are now trading at a price of $62.46. The ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Q1 2025 Earnings Call Transcript May 1, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $1.13, ...

Compared to the aggregate P/E ratio of the 52.0 in the Biotechnology industry, Biomarin Pharmaceutical Inc. has a lower P/E ...

Whilst 2025 outlooks include cost impacts from existing tariffs, companies have not adjusted their guidance for future pharma ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President - Finance; Biomarin Pharmaceutical Inc ...

Discover BioMarin's Q1 2025 highlights: 15% revenue growth, VOXZOGO's 40% surge, and innovative R&D initiatives.

On the call from BioMarin management today are Alexander Hardy, President and Chief Executive Officer; Brian Mueller, Executive Vice President, Chief Financial Officer; Cristin Hubbard, Executive Vice ...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.71 per share a year ago.

SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported first-quarter net income of $185.7 million. The San Rafael, California-based company said ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for.